טוען...
Engineering T cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing
Chimeric antigen receptor-modified T cells (CAR-T cells) have shown good effects in the treatment of hematologic cancers; however, they may cause on-target off-tumor toxicity because of minimal expression of tumor-associated antigens (TAAs) on normal tissues, particularly in the context of treating...
שמור ב:
| הוצא לאור ב: | Biomark Res |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7602323/ https://ncbi.nlm.nih.gov/pubmed/33292642 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-020-00238-9 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|